LiveWellMD Weight Loss
LiveWellMD Weight Loss · 86 North Front Street · Kingston, NY 12401
5.0· 6 Google reviews
Listing updated October 2, 2026
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- GLP-1 medications named on site
- Medically supervised weight loss
About this practice
In Kingston, New York, LiveWellMD Weight Loss lists weight-loss care, aesthetic services, and both semaglutide and tirzepatide. The brand's website describes weight loss programs and personalized care, along with skin treatments such as facials. This location has six Google reviews averaging 5.0 stars, all since 2024 and none in the past year.
Services & access
| Advertises semaglutide today | Yes |
| Advertises tirzepatide today | Yes |
| Telehealth visits | Not listed |
| Cash pay accepted | — |
| Accepts insurance — per practice website | Yes |
| Accepting new patients — per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
Counts computed by RetaMaps from public Google reviews; most recent review 2024-06-12. Read the reviews themselves on the practice's Google listing.
What patients say
Rated ★5.0 across 6 Google reviews. Of the 6 reviews we analyzed, 6 (100%) are positive (4–5★) and 0 (0%) are negative (1–2★).
Most recent Google reviews
Kimberly C.★★★★★2024-06-12Renee and her team are such an amazing support! Thank you! 😊
Carissa M.★★★★★2024-06-10Amazing experience! Easy to use, fast reaponse- highly recommend!
Analysis by RetaMaps of reviews on this practice's public Google Business listing; review themes are detected automatically and reviews reflect their authors' opinions. See all reviews on Google.
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs